The BioCentury Show

BioCentury•www.biocentury.com

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.

Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.

The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.

Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

Last refreshed: July 7th, 2025 at 12:01 AM ⓘ

Follow this podcast in the Metacast mobile app to refresh it and see new episodes.

Follow on

Apple Podcasts

Spotify

RSS

Podcasts are better in Metacast mobile app

Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episodes

Ep. 59 - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more

“I’m a short-term pessimist and a long-term optimist” about the potential for AI to transform drug development, Derek Lowe, author of the In the Pipeline blog, told BioCentury Washington Editor Steve Usdin on the latest BioCentury Show . Lowe's skepticism about claims that AI will rapidly transform the field is driven by a belief that the “problems that we have in the drug industry that we want to solve are almost inversely proportional to the ability of AI to solve them." Lowe also discussed th...

May 16, 2024•32 min•Season 3Ep. 59

Ep. 58 - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise

It sounds obvious, but still needs saying, says Ysios Capital's Karen Wagner. “How do you rise above the noise? By having the most spectacular data.” In conversation with Editor in Chief Simone Fishburn on The BioCentury Show , Wagner discussed the theme of the upcoming Bio€quity Europe conference — rising above the noise: in a sea of competition where companies vie for attention among investors and pharmas, what are the characteristics that allow them to differentiate? Wagner explains what she ...

May 02, 2024•31 min•Season 3Ep. 58

Ep. 57 - BMS's Robert Plenge: Causal biology is the North Star of R&D

This is a previously recorded episode of The BioCentury Show . Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. Within the framework of target, modality and path to clinic, causal biology is the axis along which Head of Research Robert Plenge is building and prosecuting research at Bristol Myers. It maps from late-stage decisions the company has made, such as the Karuna acquisition, to strategies in early R&D, suc...

May 02, 2024•31 min•Season 3Ep. 57

Ep. 56 - BIO’s John Crowley on the Biosecure Act

This is a previously recorded episode of The BioCentury Show . Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. BIO CEO John Crowley believes that biotech is part of a “great global rivalry” between the U.S. and China. The role of biotech in determining the outcome of this rivalry, and a belief in the need for reducing U.S. reliance on Chinese biotech companies, led BIO to reverse its opposition to the Biosecure Act. ...

Apr 17, 2024•37 min•Season 3Ep. 56

Ep. 55 - Bruce Booth: Biotech Benefiting from Belt-Tightening

This is a previously recorded episode of The BioCentury Show . Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. Atlas Venture’s Bruce Booth believes the belt-tightening by biotechs in the past few years will presage a better financing outlook for companies, but the ripple effects will be felt for some time to come. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, the longtime biotech VC sai...

Apr 17, 2024•32 min•Season 3Ep. 55

Ep. 54 - Arthur Caplan: Lessons From a Compassionate Use Firestorm

This is a previously recorded episode of The BioCentury Show . Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. On the tenth anniversary of a viral media campaign for access to an unapproved drug that extended a boy’s life, bioethicist Arthur Caplan reflected in an interview with The BioCentury Show on how the experience reshaped public views, corporate policies and legal requirements associated with providing access ...

Apr 17, 2024•31 min•Season 3Ep. 54

Ep. 53 - Bob Nelsen on AI, China and the IRA

This is a previously recorded episode of The BioCentury Show . Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. In a wide-ranging conversation with BioCentury, Bob Nelsen, co-founder and managing director of Arch Venture Partners, said he is excited by the potential for AI to “create a language of biology,” is cautious about investing in China given increasing geopolitical tensions, and is convinced that the U.S. heal...

Apr 17, 2024•35 min•Season 3Ep. 53

Ep. 52 - Khoo Shih on Scaling Singapore Biotech

This is a previously recorded episode of The BioCentury Show . Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. Success for the Singapore biotech project will take a global network, one which Khoo Shih and other prominent drivers of the local ecosystem are keen to leverage to bring the right combination of talent, experience and capital to the growing hub. Speaking on The BioCentury Show, Khoo Shih, CEO of investment ...

Apr 17, 2024•31 min•Season 3Ep. 52

← Prev

Hosted on Buzzsprout

For the best experience, listen in Metacast app for iOS or Android